Introduction: Sleep Apnea Syndrome is a syndrome with an episode of apnea or hypopnea during sleep. The objective of this study was to investigate the effect of the vitamin C therapy to plasma Malondialdehyde (MDA) level in patients with chronic tonsillitis who have a risk factor of Obstructive Sleep Apnea Syndrome (OSAS), measured pre and post-therapy.
Introduction
Sleep apnea syndrome is a syndrome with an episode of apnea or hypopnea during sleep. Apnea can be caused by central abnormalities, airway obstruction, or both. Obstructive apnea is a condition with cessation of airflow in the nose and mouth with breathing effort, whereas central apnea is a respiratory cessation that is not accompanied by breathing effort due to the absence of breath stimulation. Hypoventilation obstruction is caused by partial obstruction of air flow causing hypoventilation and hypoxia. The term hypoventilation obstruction is used to indicate the presence of hypopnea, which implies a reduction in airflow (Rosen et al., 2012; Spicuzza, Caruso, & Di Maria, 2015; Swedish Council on Health Technology, 2007) . Obstructive sleep apnea (OSA) is characterized by a period of repeated upper airway collapse that leads to a hypoxia / reoxygenation cycle causing increased oxygen species formation by oxidative stress (Patil, Schneider, Schwartz, & Smith, 2007; Sunitha & Aravindkumar, 2009 ).
Intermittent hypoxia can lead to increased oxygen-free radical formation. One of the lipid oxidation products is Malondialdehyde (MDA) which is used as biomarker on oxidative stress test. MDA is an unsaturated fatty acid oxidation product by free radicals. Increased MDA concentration indicates free radicals involvement. Oxidation reactions cause oxidative damage eventually, resulting in cell damage and death (Behn, Araneda, Llanos, Celedon, & Gonzalez, 2007; Chantharaksri, Tonsuwonnont, Fucharoen, & Wasi, 1992; Freudenthaler, Schreeb, Wiese, Pilz, & Gleiter, 2002 ).
Plasma MDA levels as a free radical biomarker was higher in patients with chronic tonsillitis who had OSAS than who had not OSAS (Asker et al., 2015; Kang, Jung, & Kim, 2013; Tauman, Lavie, Greenfeld, & Sivan, 2014) .
Increased levels of free radicals can be neutralized by antioxidants. The body has the ability to produce endogenous antioxidants such as gluthatione, superoxide dismutase, and catalase. However, these substances are not sufficient to neutralize excessive free radicals that are formed. Therefore, exogenous antioxidants was required, one example is vitamin C. Vitamin C is known as a potent compound to ward off free radicals. The use of vitamin C as one of the natural antioxidants is widely recommended in treating and detoxifying (reducing toxins) the condition. Free radical damage results in the occurrence of some diseases (Getoff, 2013; Tariq, 2007) .
The provision of vitamin C can reduce levels of Malondialdehyde (MDA), supplementation 250 mg vitamin C for 12 weeks to hemodialysis patients decreases MDA levels also prevent complications of diabetes mellitus (Abdollahzad et al., 2009; Mazloom et al., 2011) . Vitamin C supplements also increase superoxide dismutase (SOD) activity, glutathione peroxidase (GPx), the levels of vitamin E, total antioxidant capacity (TAC) and a significant decrease in MDA (Karajibani, Hashemi, Montazerifar, & Dikshit, 2010) .
Based on these, we were excited to investigate the effect of Vitamin C therapy on the level of plasma malondialdehyde (MDA) in a patient with chronic tonsillitis with the risk of obstructive sleep apnea syndrome (OSAS) at pre-and post-therapy.
Materials and Methods

Location and Period of Study
This study was conducted at ENT-Head and Neck Department Dr. Wahidin Sudirohusodo Hospital, and Hasanuddin University Teaching Hospital. The study period starts from August 2017 to January 2018.
Study Design and Variable
This study was quasi-experimental study with pre and post-test control group design. The study variables consist of: independent variable (vitamin C), dependent variable (plasma MDA level), and intermediate variables (tonsillar hypertrophy, incomplete pharyngeal obstruction, hypoxia state and free radical increase).
Population and Sample
The population of the study was all patients with chronic tonsillitis who came for treatment at ENT-Head and Neck Department Dr. Wahidin Sudirohusodo Hospital and Hasanuddin University Teaching Hospital. The study was held from August 2017 to January 2018. The study sample is part of the population that meets the inclusion criteria (chronic tonsillitis, Age 15 -40 years, disposed of and understand the assessment instructions of the Berlin questionnaire, Not taking vitamin C supplementation within the last 1 month, willing to participate in the study and give informed consent.
Ethical approve from the ethical committee of Hasanuddin University, faculty of medicine.
Intervention
History taking, ENT examination: otoscopy, anterior and posterior rhinoscopy, pharyngoscopy, indirect laryngoscopy. Those who meet the inclusion criteria are included as sample. The accompanying subject or family signed the informed consent. The subjects filled out a Berlin questionnaire containing the OSA symptom evaluation. The given vitamin C dose was 2x500 mg/patient for three weeks. Period of examination of plasma MDA level was before and after 3 weeks of therapy.
Data Analysis Technique
Plasma MDA level was examinated using enzyme-linked immunosorbent assay (ELISA) used BioAssay Technology Laboratory kit (the procedure of laboratory using its instruction) in in the laboratory of molecular biology of Hasanuddin University hospital.
All data was obtained, grouped in accordance with the purpose and type of data, to be further tested using Mann Whitney and Chi Square analysis. Data was processed using computerized system. Assessment of hypothesis test result is significant if p<0.05.
Results
Study have been conducted with pre and post-test control group design to determine the effect of Vitamin C therapy to the levels of MDA in patients with chronic tonsillitis with the risk of obstructive sleep apnea syndrome (OSAS) pre and post-therapy of vitamin C. The study was conducted at the ENT-Head and Neck Department Dr.Wahidin Sudirohusodo Hospital and Hasanuddin University Teaching Hospital from August 2017 to January 2018.
During the period, patients with chronic tonsillitis who met the inclusion criteria fill out the Berlin questionnaire to gjhs.ccsenet.org Global Journal of Health Science Vol. 10, No. 9; 2018 assess the presence of OSAS risk, then were examined to measure their plasma MDA levels. The results of this study were among 30 subjects, 20 of them were patients with chronic tonsillitis, in which half was given vitamin C therapy and the rest was not, and another 10 subjects were control.
Generalized and clinical characteristics of the results of this study illustrate the variables studied in the control group, group of chronic tonsillitis with the risk of OSAS without treatment of vitamin C (control without treatment), and group of chronic tonsillitis with the risk of OSAS with vitamin C treatment, including gender, age, BMI, tonsil size, and Berlin score. The proportion of women is higher (56.7%) than males (43.3%). The distribution of most age in groups was 15-20 year old (40%). The most common BMI was normoweight, as much as 26 subjects (86.7%). The most common tonsil enlargement were T2-T2 by 13 samples (43.4%). Berlin's highest scores are in the group with OSAS as many as 20 samples (66.7%) ( Table 1) . The association of tonsil enlargement in the control group, control with and without treatment showed a significant association with p<0.05 ( Table 2 ). The OSAS linkages in the control group, controls with and without treatment had a significant association with p <0.05 (Table 3) . Mean plasma MDA level after treatment in the control group without treatment was 9,712 μmol/l and in the treatment group was 7.053 μmol/l. This information showed no difference in plasma MDA levels after therapy in the untreated control group and treatment group (p > 0.05) ( Table 4) . The mean decrease of plasma MDA level in the group without treatment was 20,510 μmol / l, and in treatment group was -2,24 μmol / l. This indicates a significant decrease in plasma MDA levels (p <0.05). This could be interpreted also that the use of therapy with additional vitamin C can lower the plasma MDA levels in the treatment group (Table 5) . 
Discussion
This study showed that there was a decrease in plasma MDA levels in chronic tonsillitis patients with risk of OSAS after Vitamin C therapy, but there was no significant difference in plasma MDA level among chronic tonsillitis patients with the risk of OSAS given Vitamin C therapy and without therapy of Vitamin C.
Based on the results of the analysis of differences in plasma MDA levels between controls, controls with and without treatment showed significant differences in plasma MDA prior to therapy between the control group and the untreated control group (p < 0.05), and plasma MDA prior to therapy between the control group and treatment (p < 0.05). There was no significant difference in plasma MDA after treatment between the untreated control and treatment group (p > 0.05).
Increased plasma MDA levels in patients with chronic tonsillitis with the risk of OSAS caused by chronic hypoxic conditions that occur in chronic tonsillitis group with risk OSAS. This hypoxia condition results in increased formation of Reactive Oxygen Species (ROS) within the cell. ROS sources in hypoxic conditions are primarily derived from mitochondria and enzyme activity of NADP (H) oxidase and xanthine oxidase. As the product of ROS oxidation, MDA will increase and provide a picture of the damage caused by body antioxidants that can not be overcome with increased oxidant substances. Longer vitamin C therapy is required to get the maximum results, this study only interferes with vitamin C for three weeks and chronic conditions need more than three weeks to decrease MDA level significantly.
Some existing studies only intervene with vitamin C in subjects who are still healthy or have not experienced chronic conditions so that the results are maximized (Popovic et al., 2015) . Iron deficiency (female youth) needs
